Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	68.63	72.87	86.33	94.39	95.82	157.46
Short-Term Investments	0	0	0	0	2.5	27.48
Cash & Cash Equivalents	68.63	72.87	86.33	94.39	98.32	184.94
Cash Growth	-13.93%	-15.59%	-8.54%	-4.00%	-46.84%	16.31%
Receivables	32.08	35.96	34.63	29.84	24.1	23.08
Inventory	49.41	46.39	39.77	36.01	46.21	22
Other Current Assets	8.85	8.1	8.83	8.29	8.75	4.29
Total Current Assets	158.96	163.31	169.55	168.53	177.38	234.31
Property, Plant & Equipment	74.24	74.97	78.98	68.56	73.23	73.65
Goodwill and Intangibles	11.7	12.2	81.94	90.16	99.57	15.28
Other Long-Term Assets	18.84	20.16	18.67	20.29	15.42	7.48
Total Long-Term Assets	104.78	107.32	179.58	179.01	188.22	96.4
Total Assets	263.74	270.63	349.13	347.54	365.61	330.71
Accounts Payable	10.02	9.86	9.07	7.63	8.98	3.83
Other Current Liabilities	18.44	21.2	18.84	22.16	27.88	12.45
Total Current Liabilities	28.46	31.06	27.91	29.8	36.87	16.28
Long-Term Debt	26.34	26.9	28.82	19.24	20.88	21.37
Other Long-Term Liabilities	0.4	0.4	6.83	11.42	35.46	4.69
Total Long-Term Liabilities	26.75	27.31	35.65	30.66	56.34	26.06
Total Liabilities	55.21	58.37	63.57	60.45	93.21	42.33
Total Debt	26.34	26.9	28.82	19.24	20.88	21.37
Debt Growth	-6.85%	-6.64%	49.78%	-7.85%	-2.28%	-
Retained Earnings	123.54	128.05	210.72	225.58	221.44	245.43
Comprehensive Income	-6.32	-5.94	-6.44	-5.72	-4.54	-5.9
Shareholders' Equity	208.54	212.27	285.56	287.09	272.4	288.38
Net Cash / Debt	42.29	45.96	57.51	75.15	77.44	163.58
Net Cash / Debt Growth	-17.82%	-20.08%	-23.47%	-2.96%	-52.66%	2.87%
Net Cash Per Share	2.88	3.14	3.95	5.14	5.45	11.38
Working Capital	130.5	132.25	141.63	138.73	140.52	218.03
Book Value Per Share	14.19	14.48	19.61	19.93	19.15	20.42

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).